ATE467617T1 - Biphenylverbindungen geeignet für die synthese von muscarinrezeptorantagonisten - Google Patents

Biphenylverbindungen geeignet für die synthese von muscarinrezeptorantagonisten

Info

Publication number
ATE467617T1
ATE467617T1 AT08151157T AT08151157T ATE467617T1 AT E467617 T1 ATE467617 T1 AT E467617T1 AT 08151157 T AT08151157 T AT 08151157T AT 08151157 T AT08151157 T AT 08151157T AT E467617 T1 ATE467617 T1 AT E467617T1
Authority
AT
Austria
Prior art keywords
synthesis
receptor antagonists
compounds suitable
biphenyl compounds
muscarine receptor
Prior art date
Application number
AT08151157T
Other languages
English (en)
Inventor
Mathai Mammen
Yu-Hua Ji
Yongqi Mu
Craig Husfeld
Li Li
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of ATE467617T1 publication Critical patent/ATE467617T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT08151157T 2004-03-11 2005-03-10 Biphenylverbindungen geeignet für die synthese von muscarinrezeptorantagonisten ATE467617T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55244304P 2004-03-11 2004-03-11

Publications (1)

Publication Number Publication Date
ATE467617T1 true ATE467617T1 (de) 2010-05-15

Family

ID=34963910

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08151157T ATE467617T1 (de) 2004-03-11 2005-03-10 Biphenylverbindungen geeignet für die synthese von muscarinrezeptorantagonisten
AT05730087T ATE395335T1 (de) 2004-03-11 2005-03-10 Als muscarinrezeptorantagonisten geeignete biphenylverbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05730087T ATE395335T1 (de) 2004-03-11 2005-03-10 Als muscarinrezeptorantagonisten geeignete biphenylverbindungen

Country Status (28)

Country Link
US (22) US7288657B2 (de)
EP (2) EP1930323B1 (de)
JP (1) JP4837653B2 (de)
KR (1) KR101174740B1 (de)
CN (1) CN1930125B (de)
AR (2) AR048032A1 (de)
AT (2) ATE467617T1 (de)
AU (1) AU2005222411B2 (de)
BR (1) BRPI0508622B8 (de)
CA (1) CA2557479C (de)
CY (1) CY1109015T1 (de)
DE (2) DE602005021258D1 (de)
DK (1) DK1723114T3 (de)
ES (2) ES2306125T3 (de)
HK (2) HK1097537A1 (de)
HR (1) HRP20080301T3 (de)
IL (1) IL177359A (de)
MA (1) MA28524B1 (de)
MY (1) MY144482A (de)
NO (1) NO338941B1 (de)
NZ (1) NZ549472A (de)
PL (1) PL1723114T3 (de)
PT (1) PT1723114E (de)
RU (1) RU2366656C2 (de)
SI (1) SI1723114T1 (de)
TW (1) TWI341836B (de)
WO (1) WO2005087738A1 (de)
ZA (1) ZA200607099B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528412A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物
US7456199B2 (en) * 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7524962B2 (en) * 2004-03-11 2009-04-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528408A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
US7560469B2 (en) * 2004-03-11 2009-07-14 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
TWI372749B (en) * 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
EP1856112A1 (de) * 2005-03-10 2007-11-21 Theravance, Inc. Biphenylverbindungen als muscarinrezeptor-antagonisten
JP2008537931A (ja) * 2005-03-10 2008-10-02 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7642355B2 (en) * 2005-03-10 2010-01-05 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006138218A1 (en) * 2005-06-13 2006-12-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US8138345B2 (en) 2009-04-23 2012-03-20 Theravance, Inc. Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
JP5651174B2 (ja) 2009-07-15 2015-01-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ビフェニル化合物の結晶性遊離塩基形
CN102958916B (zh) 2010-07-13 2015-03-25 施万生物制药研发Ip有限责任公司 制备联苯-2-基氨基甲酸的方法
WO2012106382A1 (en) * 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9679336B2 (en) * 2011-10-19 2017-06-13 Facebook, Inc. Social ad hoc networking protocol and presentation layer
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
CN107849047B (zh) * 2015-09-28 2021-01-15 四川海思科制药有限公司 一种联苯衍生物及其制备方法和在医药上的用途
CN106565674B (zh) * 2015-10-13 2021-02-05 四川海思科制药有限公司 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
US11591323B2 (en) * 2019-03-06 2023-02-28 Barry university Muscarinic agonists as non-steroidal and non-opioid analgesics and methods of use thereof
CN110526859B (zh) * 2019-08-07 2021-03-12 山东百诺医药股份有限公司 一种瑞维那新中间体及其制备方法和瑞维那新的制备方法
CN112694434B (zh) * 2020-12-29 2023-06-16 浙江和泽医药科技股份有限公司 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法
WO2023017404A1 (en) * 2021-08-13 2023-02-16 Begum Dr M Sasthaa A device, a compound, for inhalation of an anti-viral agent
CN118401497A (zh) 2021-12-09 2024-07-26 医药化学公司 雷芬那辛的结晶型丙酮溶剂化物
CN117263848A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛的吸入喷雾剂

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US747952A (en) * 1903-03-02 1903-12-29 Harry Cauley Dillon Ironing-board.
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
PH26882A (en) 1985-07-30 1992-11-16 Glaxo Group Ltd Devices for administering medicaments to patients
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
HU0004452D0 (de) * 1991-12-18 2001-01-29 Astra Ab
EP0617610B1 (de) 1991-12-18 1997-03-19 Minnesota Mining And Manufacturing Company Aerosolzusammensetzungen für arzneimittelsuspensionen
GB9206989D0 (en) * 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
WO1995006635A1 (fr) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
CA2182568A1 (en) 1994-02-10 1995-08-17 Makoto Takeuchi Novel carbamate derivative and medicinal composition containing the same
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
RU2126001C1 (ru) * 1995-01-10 1999-02-10 Самдзин Фармасьютикал Ко., Лтд Производные пиперазина и фармацевтическая композиция на их основе
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
CN1142798C (zh) 1995-04-14 2004-03-24 葛兰素惠尔康公司 沙美特罗的计定剂量吸入器
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
EP1070056B1 (de) 1998-03-14 2004-06-30 ALTANA Pharma AG Phthalazinone pde iii/iv hemmer
AU755066B2 (en) 1998-04-18 2002-12-05 Glaxo Group Limited Pharmaceutical aerosol formulation
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
EP1086066A4 (de) 1998-06-08 2001-08-08 Advanced Medicine Inc Muskarinrezeptorantagonisten
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE60001492T2 (de) 1999-04-14 2003-12-18 Glaxo Group Ltd., Greenford Pharmazeutische aerosolformulierung
DE19933926A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US6510182B1 (en) * 1999-10-25 2003-01-21 Freesystems Pte. Ltd. Wireless infrared digital audio system
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
ATE299494T1 (de) 1999-12-07 2005-07-15 Theravance Inc Carbamat-derivate als muscarin-rezeptor antonisten
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
KR100869722B1 (ko) 2000-12-22 2008-11-21 알미랄 에이쥐 퀴누클리딘 카르바메이트 유도체 및 ｍ3 길항제로서 그의사용
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002070490A1 (en) 2001-03-08 2002-09-12 Glaxo Group Limited Agonists of beta-adrenoceptors
DE60224172T2 (de) 2001-03-22 2008-12-04 Glaxo Group Ltd., Greenford Formanilid-derivative als beta2-adrenorezeptor-agonisten
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DK1425001T3 (da) 2001-09-14 2009-04-14 Glaxo Group Ltd Phenethanolaminderivater til behandling af respiratoriske sygdomme
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
AU2003258507A1 (en) 2002-07-30 2004-02-23 Unilever Plc Abrasive hard surface cleaning compositions
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CA2543858C (en) 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2007528408A (ja) 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7456199B2 (en) 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528412A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物
WO2005087734A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7560469B2 (en) 2004-03-11 2009-07-14 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7524962B2 (en) 2004-03-11 2009-04-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1856112A1 (de) 2005-03-10 2007-11-21 Theravance, Inc. Biphenylverbindungen als muscarinrezeptor-antagonisten
US7642355B2 (en) * 2005-03-10 2010-01-05 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) * 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
JP2008537931A (ja) * 2005-03-10 2008-10-02 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006138218A1 (en) 2005-06-13 2006-12-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US20070029346A1 (en) * 2005-08-03 2007-02-08 Fu-Tian Hung Pneumatic greaser
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
CA2861601A1 (en) * 2006-04-27 2007-11-08 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
JP5651174B2 (ja) 2009-07-15 2015-01-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ビフェニル化合物の結晶性遊離塩基形
CN102958916B (zh) 2010-07-13 2015-03-25 施万生物制药研发Ip有限责任公司 制备联苯-2-基氨基甲酸的方法

Also Published As

Publication number Publication date
US8017783B2 (en) 2011-09-13
CA2557479C (en) 2013-05-07
US8273894B2 (en) 2012-09-25
US20160220551A1 (en) 2016-08-04
US20090018165A1 (en) 2009-01-15
EP1723114B1 (de) 2008-05-14
US7910608B2 (en) 2011-03-22
DE602005021258D1 (de) 2010-06-24
RU2366656C2 (ru) 2009-09-10
US20070265305A1 (en) 2007-11-15
EP1930323B1 (de) 2010-05-12
US20200290966A1 (en) 2020-09-17
US7803812B2 (en) 2010-09-28
US20180179161A1 (en) 2018-06-28
US10106503B2 (en) 2018-10-23
WO2005087738A1 (en) 2005-09-22
ES2306125T3 (es) 2008-11-01
EP1723114A1 (de) 2006-11-22
US8173815B2 (en) 2012-05-08
AR048032A1 (es) 2006-03-22
CN1930125A (zh) 2007-03-14
US20090226379A1 (en) 2009-09-10
US20080071088A1 (en) 2008-03-20
TW200538438A (en) 2005-12-01
NO20064579L (no) 2006-11-08
PL1723114T3 (pl) 2008-10-31
PT1723114E (pt) 2008-07-17
US8053448B2 (en) 2011-11-08
US9926272B2 (en) 2018-03-27
US7288657B2 (en) 2007-10-30
JP4837653B2 (ja) 2011-12-14
US20120190657A1 (en) 2012-07-26
US20170204061A1 (en) 2017-07-20
NO338941B1 (no) 2016-10-31
AR104444A2 (es) 2017-07-19
US7491736B2 (en) 2009-02-17
DE602005006757D1 (de) 2008-06-26
US7585879B2 (en) 2009-09-08
IL177359A (en) 2012-04-30
SI1723114T1 (sl) 2008-08-31
IL177359A0 (en) 2006-12-10
ZA200607099B (en) 2008-09-25
EP1930323A1 (de) 2008-06-11
US20070292356A1 (en) 2007-12-20
US10343995B2 (en) 2019-07-09
HK1097537A1 (en) 2007-06-29
BRPI0508622A (pt) 2007-07-31
US9452161B2 (en) 2016-09-27
CN1930125B (zh) 2010-07-21
MY144482A (en) 2011-09-30
DK1723114T3 (da) 2008-07-28
US9283183B2 (en) 2016-03-15
AU2005222411B2 (en) 2011-04-21
JP2008532922A (ja) 2008-08-21
US20150164795A1 (en) 2015-06-18
BRPI0508622B1 (pt) 2018-05-22
US20110130422A1 (en) 2011-06-02
US20080095708A1 (en) 2008-04-24
US10570092B2 (en) 2020-02-25
CY1109015T1 (el) 2014-07-02
ATE395335T1 (de) 2008-05-15
KR101174740B1 (ko) 2012-08-17
US8034946B2 (en) 2011-10-11
US20190047957A1 (en) 2019-02-14
US20220306579A1 (en) 2022-09-29
CA2557479A1 (en) 2005-09-22
BRPI0508622B8 (pt) 2021-05-25
US8557997B2 (en) 2013-10-15
US20070292357A1 (en) 2007-12-20
NZ549472A (en) 2010-06-25
US7521041B2 (en) 2009-04-21
US7550595B2 (en) 2009-06-23
US20110319625A1 (en) 2011-12-29
US20190359570A1 (en) 2019-11-28
KR20070011370A (ko) 2007-01-24
HK1119672A1 (en) 2009-03-13
ES2345640T3 (es) 2010-09-28
US20130172301A1 (en) 2013-07-04
TWI341836B (en) 2011-05-11
US8912334B2 (en) 2014-12-16
US20140171397A1 (en) 2014-06-19
US11247969B2 (en) 2022-02-15
RU2006135927A (ru) 2008-04-20
US20050203133A1 (en) 2005-09-15
HRP20080301T3 (en) 2008-09-30
US20100249421A1 (en) 2010-09-30
MA28524B1 (fr) 2007-04-03
AU2005222411A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
ATE467617T1 (de) Biphenylverbindungen geeignet für die synthese von muscarinrezeptorantagonisten
CY2017008I2 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
DK1677795T3 (da) Muskarine acetylcholin-receptor-antagonister
DK1951660T3 (da) Histamin-3-receptorantagonister
ATE486853T1 (de) Synthese von acylaminoalkenylenamiden als substanz-p-antagonisten
NL1028624A1 (nl) Alfa-aryl- of -heteroarylmethyl-bèta-piperidinopropaan-zuurverbindingen als ORL1-receptorantagonisten.
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
ES2380489T8 (es) Proceso para la síntesis de compuestos orgánicos
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
DK1638969T3 (da) CGRP-receptorantagonister
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
IL185892A0 (en) Novel compounds and their isomers and pharmaceutical compositions containing the same as vanilloid receptor antagonists
ZA200801035B (en) Substituted piperazines as metabotropic glutamate receptor antagonists
DK2089367T3 (da) Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
ATE420069T1 (de) Carboxamid derivate als muskarin rezeptor antagonisten
DE602004021965D1 (de) Vertikale arbeitslinie für plattenmaterial
ATE500249T1 (de) Synthese von himbacinanaloga
DK1725223T3 (da) Anvendelse af antagonister til CB1-receptoren til fremstilling af en sammensætning, der er anvendelig til behandling af leversygdomme
ATE553108T1 (de) Thiazoloä4,5-cüpyridinderivative als antagonisten des mglu5-rezeptors
ATE484500T1 (de) Synthese von ccr5 rezeptor antagonisten
IL188808A0 (en) Bicyclic piperazines as metabotropic glutamate receptor antagonists
DE602006018334D1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
FR2921656B1 (fr) Procede de synthese d'arylamines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties